HAVCR2 and neoplasm: Several ongoing clinical trials have evaluated the effect of integrating TIM-3 inhibitor into existing treatment of cancer, including the combination of the anti-TIM-3 antibody sabatolimab with the anti-PD-1 antibody spartalizumab in advanced solid tumors, which showed good anti-tumor efficacy and acceptable tolerability [16].